SCHEMBL2976805

SCHEMBL2976805

CC(OCc1cccc(-n2cnc3cc(CN)ccc32)c1)c1ncc[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 2/20 0.44
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
GABRA3 P34903 3/20 0.39
GABRA2 P47869 3/20 0.39
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRB1 P18505 2/20 0.39
GABRB2 P47870 2/20 0.39
GABRA4 P48169 2/20 0.39
GABRE P78334 2/20 0.39
GABRA6 Q16445 2/20 0.39
GABRG1 Q8N1C3 2/20 0.39
GABRG3 Q99928 2/20 0.39
GABRQ Q9UN88 2/20 0.39
FGFR1 P11362 13/20 0.38
SRC P12931 3/20 0.35
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977950 0.91 FGFR1 (0.39) PRKCIGABRA1GABRG2GABRB3GABRA5
SCHEMBL2974092 0.91 FGFR1 (0.38) PRKCIGABRA1GABRG2GABRB3GABRA5
SCHEMBL2963434 0.87 SIGMAR1 (0.38) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2966390 0.85 FGFR1 (0.44) PRKCIFGFR1SRCMAPK1SMN1; SMN2
SCHEMBL2652696 0.84 FGFR1 (0.36) PRKCIGABRA1GABRG2GABRB3GABRA5
SCHEMBL2653928 0.83 GABRP (0.40) PRKCIGABRA1GABRG2GABRB3GABRA5
SCHEMBL2659958 0.83 PRKCI (0.35) PRKCIGABRA1GABRG2GABRB3GABRA5
SCHEMBL2964600 0.82 HPGD (0.45) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2977952 0.76 HPGD (0.37) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2974099 0.74 HPGD (0.39) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 PRKCI 1218/4885GABRA1 8/4885GABRG2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.